The NEJM published favorable results of a phase 3 trial of the alpha interferon inhibitor, anifrolumab, showing it to be superior to placebo in active systemic lupus erythematosus (SLE) patients studied for 48 weeks.
Dr. John Cush RheumNow
6 years 9 months ago
Early Lupus study of 230 pts -Assess by SLICC/ACR Damage Index - 22% had Damage Index ≥1 after 12 months, 26% qt 2 yrs and 29%) @ 3 yrs. Risk factors included Dyslipidaemia (HR 2.9), older age (3.0), #organs/systems (1.4), CVresp Dz (1.9) https://t.co/JUrgTN5hII
French researchers have shown that patients with systemic lupus erythematosus (SLE) and inactive disease are less likely to flare while taking a 5 mg prednisone maintenance dose.
Dr. John Cush RheumNow
6 years 9 months ago
Why are we guessing? A 20 yr #RA pt, Severe, erosive, polyarticular CCP+ RA, failed MTX, SSZ, Enbrel, Humira, Cimzia, Xeljanz, Orencia; had TJC 22, SJC 18, CDAI 37; put on LEF & IL-6 inhib & 2 mos later SJC 2, CDAI 3! HELP! We need a better way! AI #bigdata, #realbiomarkers
At the recent ACR 2019 meeting, I met some incredible women who shared with me their struggles, sacrifices and success when it comes to balancing a career and family while still retaining their sense of self. Many of you know I am a mother to 3 children ages 15, 12 and 9. Life can be challenging, especially since my husband has a busy practice, too. So how do you advance your career and still raise a family? Here are five lessons I've learned.
Dr. John Cush RheumNow
6 years 10 months ago
In Southern Sweden, the prevalence of non-gout crystal arthropathy (>1/3 of which was CPPD) is 0.23%, w/ meage of 71 yrs, more in men and increases w/ age. The incidence is 21.5 (19–25) cases/100,000 persons. https://t.co/MLIhxBPUSO
Reuters - Doctors rarely talk about weight concerns with patients who are overweight or obese, and when they do, patients’ experiences tend to be negative, according to a new review of research based on interviews.
The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.
Dr. John Cush RheumNow
6 years 10 months ago
Should AS/SpA pts have ECHO for AI/AR? I say YES; Swedish study of 6448 AS pts shows 2 fold higher risk AI https://t.co/lchlsGXAJi. Another ECHO study 187 AS pts shows an incr prevalence (18%) of AI murmur esp w/ longstanding disease or age >50 (>50%) https://t.co/Np21FwCbBP
Dr. John Cush RheumNow
6 years 10 months ago
There is a 2 fold higher rate of RE-Vertebral fractures in Primary Osteoporosis patients who had a previous percutaneous vertebroplasty (PVP) and when taking steroids (vs no steroids). https://t.co/rQaqZnmaD5
Dr. John Cush RheumNow
6 years 10 months ago
retrospective cohort study of CCP+ individuals without RA, were followed, showing that they were more likely to progress to RA in 5 yrs if they had high CCP antibody levels (46%). (HR 4.83 [95% CI 2.51–9.31]) https://t.co/Vuaqly1M5Y
Domestic violence was found to predispose to a higher risk of fibromyalgia and those developing chronic fatigue syndrome.
Researchers studied the association between intimate partner violence (IPV) with fibromyalgia and CFS, using a retrospective open cohort design of patients entered into the “The Heath Improvement Network” database between 1995 and 2017.
The French Vasculitis Study Group has published that patients with systemic necrotizing vasculitis do not have an increased risk of malignancy; in fact they have a risk that is similar to the general population.
Previous reports have suggested either no risk or a declining risk in the era of better therapies for vasculitis.
Dr. John Cush RheumNow
6 years 10 months ago
From 2007 to 2018, claims for Lyme disease increased nationally 117%, from 0.027% of all medical claims to 0.058%. Most affected states were New Jersey, Rhode Island, Connecticut, Massachusetts and New York https://t.co/v4XF97O0bU
Dr. John Cush RheumNow
6 years 10 months ago
Retrospective cohort study of 154 RA patients undergoing 244 major surgeries in shows that perioperative use of DMARDs (39%) or biologics (13%) was not associated with 30-day odds of post-operative infection #ACR19 Abst #1805 https://t.co/7poDnUhRNf

